APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psilocybin Assisted Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psilocybin Assisted Therapy Market Outlook and Growth Opportunities 2026

31 December 2025199 pages

Choose your research edition.

Industry ResearchPsilocybin Assisted Therapy Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Psilocybin Assisted Therapy Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Psilocybin Assisted Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psilocybin Assisted Therapy Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Psilocybin Assisted Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Psilocybin Assisted Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psilocybin Assisted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psilocybin Assisted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psilocybin Assisted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psilocybin Assisted Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psilocybin Assisted Therapy market include ATAI Life Sciences, Compass Pathways, DemeRx, Eleusis, Field Trip, Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals, MindMed and Verrian, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Psilocybin Assisted Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psilocybin Assisted Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psilocybin Assisted Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Psilocybin Assisted Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Psilocybin Assisted Therapy Segment by Company

ATAI Life Sciences

Compass Pathways

DemeRx

Eleusis

Field Trip

Hikma Pharmaceuticals PLC

Jazz Pharmaceuticals

MindMed

Verrian

Pfizer

Psilocybin Assisted Therapy Segment by Type

Natural

Synthetic

Psilocybin Assisted Therapy Segment by Application

Psychiatric Disorders

Anxiety Disorders

Cluster Headaches

Psilocybin Assisted Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Psilocybin Assisted Therapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Psilocybin Assisted Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psilocybin Assisted Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Psilocybin Assisted Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psilocybin Assisted Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psilocybin Assisted Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psilocybin Assisted Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Psilocybin Assisted Therapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psilocybin Assisted Therapy industry.

Chapter 3: Detailed analysis of Psilocybin Assisted Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Psilocybin Assisted Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Psilocybin Assisted Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psilocybin Assisted Therapy Industry Trends Table 2. Psilocybin Assisted Therapy Industry Drivers Table 3. Psilocybin Assisted Therapy Industry Opportunities and Challenges Table 4. Psilocybin Assisted Therapy Industry Restraints Table 5. Global Psilocybin Assisted Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psilocybin Assisted Therapy Revenue Share by Company (2021-2026) Table 7. Global Psilocybin Assisted Therapy Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Psilocybin Assisted Therapy Sales Volume Share by Company (2021-2026) Table 9. Global Psilocybin Assisted Therapy Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Psilocybin Assisted Therapy Company Ranking, (2024-2026) & (USD Million) Table 11. Global Psilocybin Assisted Therapy Key Company Manufacturing Base & Headquarters Table 12. Global Psilocybin Assisted Therapy Company, Product Type & Application Table 13. Global Psilocybin Assisted Therapy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Psilocybin Assisted Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Natural Table 18. Significant Companies of Synthetic Table 19. Global Psilocybin Assisted Therapy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Psilocybin Assisted Therapy Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Psilocybin Assisted Therapy Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Psilocybin Assisted Therapy Sales Volume Share by Type (2021-2026) Table 23. Global Psilocybin Assisted Therapy Sales Volume Share by Type (2027-2032) Table 24. Global Psilocybin Assisted Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Psilocybin Assisted Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Psilocybin Assisted Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Psilocybin Assisted Therapy Sales Value Share by Type (2021-2026) Table 28. Global Psilocybin Assisted Therapy Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Psychiatric Disorders Table 30. Significant Companies of Anxiety Disorders Table 31. Significant Companies of Cluster Headaches Table 32. Global Psilocybin Assisted Therapy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Psilocybin Assisted Therapy Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Psilocybin Assisted Therapy Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Psilocybin Assisted Therapy Sales Volume Share by Application (2021-2026) Table 36. Global Psilocybin Assisted Therapy Sales Volume Share by Application (2027-2032) Table 37. Global Psilocybin Assisted Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Psilocybin Assisted Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Psilocybin Assisted Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Psilocybin Assisted Therapy Sales Value Share by Application (2021-2026) Table 41. Global Psilocybin Assisted Therapy Sales Value Share by Application (2027-2032) Table 42. Global Psilocybin Assisted Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Psilocybin Assisted Therapy Sales by Region (2021-2026) & (K Units) Table 44. Global Psilocybin Assisted Therapy Sales Market Share by Region (2021-2026) Table 45. Global Psilocybin Assisted Therapy Sales by Region (2027-2032) & (K Units) Table 46. Global Psilocybin Assisted Therapy Sales Market Share by Region (2027-2032) Table 47. Global Psilocybin Assisted Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Psilocybin Assisted Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Psilocybin Assisted Therapy Sales Value Share by Region (2021-2026) Table 50. Global Psilocybin Assisted Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Psilocybin Assisted Therapy Sales Value Share by Region (2027-2032) Table 52. Global Psilocybin Assisted Therapy Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Psilocybin Assisted Therapy Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Psilocybin Assisted Therapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Psilocybin Assisted Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Psilocybin Assisted Therapy Sales by Country (2021-2026) & (K Units) Table 57. Global Psilocybin Assisted Therapy Sales Market Share by Country (2021-2026) Table 58. Global Psilocybin Assisted Therapy Sales by Country (2027-2032) & (K Units) Table 59. Global Psilocybin Assisted Therapy Sales Market Share by Country (2027-2032) Table 60. Global Psilocybin Assisted Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Psilocybin Assisted Therapy Sales Value Market Share by Country (2021-2026) Table 62. Global Psilocybin Assisted Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Psilocybin Assisted Therapy Sales Value Market Share by Country (2027-2032) Table 64. ATAI Life Sciences Company Information Table 65. ATAI Life Sciences Business Overview Table 66. ATAI Life Sciences Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. ATAI Life Sciences Psilocybin Assisted Therapy Product Portfolio Table 68. ATAI Life Sciences Recent Development Table 69. Compass Pathways Company Information Table 70. Compass Pathways Business Overview Table 71. Compass Pathways Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Compass Pathways Psilocybin Assisted Therapy Product Portfolio Table 73. Compass Pathways Recent Development Table 74. DemeRx Company Information Table 75. DemeRx Business Overview Table 76. DemeRx Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. DemeRx Psilocybin Assisted Therapy Product Portfolio Table 78. DemeRx Recent Development Table 79. Eleusis Company Information Table 80. Eleusis Business Overview Table 81. Eleusis Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Eleusis Psilocybin Assisted Therapy Product Portfolio Table 83. Eleusis Recent Development Table 84. Field Trip Company Information Table 85. Field Trip Business Overview Table 86. Field Trip Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Field Trip Psilocybin Assisted Therapy Product Portfolio Table 88. Field Trip Recent Development Table 89. Hikma Pharmaceuticals PLC Company Information Table 90. Hikma Pharmaceuticals PLC Business Overview Table 91. Hikma Pharmaceuticals PLC Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Hikma Pharmaceuticals PLC Psilocybin Assisted Therapy Product Portfolio Table 93. Hikma Pharmaceuticals PLC Recent Development Table 94. Jazz Pharmaceuticals Company Information Table 95. Jazz Pharmaceuticals Business Overview Table 96. Jazz Pharmaceuticals Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Jazz Pharmaceuticals Psilocybin Assisted Therapy Product Portfolio Table 98. Jazz Pharmaceuticals Recent Development Table 99. MindMed Company Information Table 100. MindMed Business Overview Table 101. MindMed Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. MindMed Psilocybin Assisted Therapy Product Portfolio Table 103. MindMed Recent Development Table 104. Verrian Company Information Table 105. Verrian Business Overview Table 106. Verrian Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Verrian Psilocybin Assisted Therapy Product Portfolio Table 108. Verrian Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Psilocybin Assisted Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Pfizer Psilocybin Assisted Therapy Product Portfolio Table 113. Pfizer Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Psilocybin Assisted Therapy Distributors List Table 117. Psilocybin Assisted Therapy Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Psilocybin Assisted Therapy Product Image Figure 2. Global Psilocybin Assisted Therapy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 4. Global Psilocybin Assisted Therapy Sales (2021-2032) & (K Units) Figure 5. Global Psilocybin Assisted Therapy Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Psilocybin Assisted Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Natural Image Figure 10. Synthetic Image Figure 11. Global Psilocybin Assisted Therapy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Psilocybin Assisted Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Psilocybin Assisted Therapy Sales Volume Share by Type (2021-2032) Figure 14. Global Psilocybin Assisted Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Psilocybin Assisted Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Psilocybin Assisted Therapy Sales Value Share by Type (2021-2032) Figure 17. Psychiatric Disorders Image Figure 18. Anxiety Disorders Image Figure 19. Cluster Headaches Image Figure 20. Global Psilocybin Assisted Therapy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Psilocybin Assisted Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Psilocybin Assisted Therapy Sales Volume Share by Application (2021-2032) Figure 23. Global Psilocybin Assisted Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Psilocybin Assisted Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Psilocybin Assisted Therapy Sales Value Share by Application (2021-2032) Figure 26. Global Psilocybin Assisted Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Psilocybin Assisted Therapy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Psilocybin Assisted Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Psilocybin Assisted Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 31. North America Psilocybin Assisted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Psilocybin Assisted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Psilocybin Assisted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 37. South America Psilocybin Assisted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Psilocybin Assisted Therapy Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Psilocybin Assisted Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Psilocybin Assisted Therapy Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Psilocybin Assisted Therapy Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Natural
  • Synthetic
Applications
  • Psychiatric Disorders
  • Anxiety Disorders
  • Cluster Headaches
Companies covered
  • ATAI Life Sciences
  • Compass Pathways
  • DemeRx
  • Eleusis
  • Field Trip
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals
  • MindMed
  • Verrian
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Psilocybin Assisted Therapy Sales Value (2021-2032)
  4. 1.2.2 Global Psilocybin Assisted Therapy Sales Volume (2021-2032)
  5. 1.2.3 Global Psilocybin Assisted Therapy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Psilocybin Assisted Therapy Market Dynamics
  1. 2.1 Psilocybin Assisted Therapy Industry Trends
  2. 2.2 Psilocybin Assisted Therapy Industry Drivers
  3. 2.3 Psilocybin Assisted Therapy Industry Opportunities and Challenges
  4. 2.4 Psilocybin Assisted Therapy Industry Restraints
3 Psilocybin Assisted Therapy Market by Company
  1. 3.1 Global Psilocybin Assisted Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Psilocybin Assisted Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Psilocybin Assisted Therapy Sales Volume by Company (2021-2026)
  4. 3.4 Global Psilocybin Assisted Therapy Average Price by Company (2021-2026)
  5. 3.5 Global Psilocybin Assisted Therapy Company Ranking (2024-2026)
  6. 3.6 Global Psilocybin Assisted Therapy Company Manufacturing Base and Headquarters
  7. 3.7 Global Psilocybin Assisted Therapy Company Product Type and Application
  8. 3.8 Global Psilocybin Assisted Therapy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Psilocybin Assisted Therapy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Psilocybin Assisted Therapy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Psilocybin Assisted Therapy Market by Type
  1. 4.1 Psilocybin Assisted Therapy Type Introduction
  2. 4.1.1 Natural
  3. 4.1.2 Synthetic
  4. 4.2 Global Psilocybin Assisted Therapy Sales Volume by Type
  5. 4.2.1 Global Psilocybin Assisted Therapy Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Psilocybin Assisted Therapy Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Psilocybin Assisted Therapy Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Psilocybin Assisted Therapy Sales Value by Type
  9. 4.3.1 Global Psilocybin Assisted Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Psilocybin Assisted Therapy Sales Value by Type (2021-2032)
  11. 4.3.3 Global Psilocybin Assisted Therapy Sales Value Share by Type (2021-2032)
5 Psilocybin Assisted Therapy Market by Application
  1. 5.1 Psilocybin Assisted Therapy Application Introduction
  2. 5.1.1 Psychiatric Disorders
  3. 5.1.2 Anxiety Disorders
  4. 5.1.3 Cluster Headaches
  5. 5.2 Global Psilocybin Assisted Therapy Sales Volume by Application
  6. 5.2.1 Global Psilocybin Assisted Therapy Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Psilocybin Assisted Therapy Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Psilocybin Assisted Therapy Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Psilocybin Assisted Therapy Sales Value by Application
  10. 5.3.1 Global Psilocybin Assisted Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Psilocybin Assisted Therapy Sales Value by Application (2021-2032)
  12. 5.3.3 Global Psilocybin Assisted Therapy Sales Value Share by Application (2021-2032)
6 Psilocybin Assisted Therapy Regional Sales and Value Analysis
  1. 6.1 Global Psilocybin Assisted Therapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psilocybin Assisted Therapy Sales by Region (2021-2032)
  3. 6.2.1 Global Psilocybin Assisted Therapy Sales by Region: 2021-2026
  4. 6.2.2 Global Psilocybin Assisted Therapy Sales by Region (2027-2032)
  5. 6.3 Global Psilocybin Assisted Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Psilocybin Assisted Therapy Sales Value by Region (2021-2032)
  7. 6.4.1 Global Psilocybin Assisted Therapy Sales Value by Region: 2021-2026
  8. 6.4.2 Global Psilocybin Assisted Therapy Sales Value by Region (2027-2032)
  9. 6.5 Global Psilocybin Assisted Therapy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Psilocybin Assisted Therapy Sales Value (2021-2032)
  12. 6.6.2 North America Psilocybin Assisted Therapy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Psilocybin Assisted Therapy Sales Value (2021-2032)
  15. 6.7.2 Europe Psilocybin Assisted Therapy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Psilocybin Assisted Therapy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Psilocybin Assisted Therapy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Psilocybin Assisted Therapy Sales Value (2021-2032)
  21. 6.9.2 South America Psilocybin Assisted Therapy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Psilocybin Assisted Therapy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Psilocybin Assisted Therapy Sales Value Share by Country, 2025 VS 2032
7 Psilocybin Assisted Therapy Country-level Sales and Value Analysis
  1. 7.1 Global Psilocybin Assisted Therapy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psilocybin Assisted Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Psilocybin Assisted Therapy Sales by Country (2021-2032)
  4. 7.3.1 Global Psilocybin Assisted Therapy Sales by Country (2021-2026)
  5. 7.3.2 Global Psilocybin Assisted Therapy Sales by Country (2027-2032)
  6. 7.4 Global Psilocybin Assisted Therapy Sales Value by Country (2021-2032)
  7. 7.4.1 Global Psilocybin Assisted Therapy Sales Value by Country (2021-2026)
  8. 7.4.2 Global Psilocybin Assisted Therapy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Psilocybin Assisted Therapy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Psilocybin Assisted Therapy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Psilocybin Assisted Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ATAI Life Sciences
  2. 8.1.1 ATAI Life Sciences Company Information
  3. 8.1.2 ATAI Life Sciences Business Overview
  4. 8.1.3 ATAI Life Sciences Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ATAI Life Sciences Psilocybin Assisted Therapy Product Portfolio
  6. 8.1.5 ATAI Life Sciences Recent Developments
  7. 8.2 Compass Pathways
  8. 8.2.1 Compass Pathways Company Information
  9. 8.2.2 Compass Pathways Business Overview
  10. 8.2.3 Compass Pathways Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Compass Pathways Psilocybin Assisted Therapy Product Portfolio
  12. 8.2.5 Compass Pathways Recent Developments
  13. 8.3 DemeRx
  14. 8.3.1 DemeRx Company Information
  15. 8.3.2 DemeRx Business Overview
  16. 8.3.3 DemeRx Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 DemeRx Psilocybin Assisted Therapy Product Portfolio
  18. 8.3.5 DemeRx Recent Developments
  19. 8.4 Eleusis
  20. 8.4.1 Eleusis Company Information
  21. 8.4.2 Eleusis Business Overview
  22. 8.4.3 Eleusis Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eleusis Psilocybin Assisted Therapy Product Portfolio
  24. 8.4.5 Eleusis Recent Developments
  25. 8.5 Field Trip
  26. 8.5.1 Field Trip Company Information
  27. 8.5.2 Field Trip Business Overview
  28. 8.5.3 Field Trip Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Field Trip Psilocybin Assisted Therapy Product Portfolio
  30. 8.5.5 Field Trip Recent Developments
  31. 8.6 Hikma Pharmaceuticals PLC
  32. 8.6.1 Hikma Pharmaceuticals PLC Company Information
  33. 8.6.2 Hikma Pharmaceuticals PLC Business Overview
  34. 8.6.3 Hikma Pharmaceuticals PLC Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hikma Pharmaceuticals PLC Psilocybin Assisted Therapy Product Portfolio
  36. 8.6.5 Hikma Pharmaceuticals PLC Recent Developments
  37. 8.7 Jazz Pharmaceuticals
  38. 8.7.1 Jazz Pharmaceuticals Company Information
  39. 8.7.2 Jazz Pharmaceuticals Business Overview
  40. 8.7.3 Jazz Pharmaceuticals Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jazz Pharmaceuticals Psilocybin Assisted Therapy Product Portfolio
  42. 8.7.5 Jazz Pharmaceuticals Recent Developments
  43. 8.8 MindMed
  44. 8.8.1 MindMed Company Information
  45. 8.8.2 MindMed Business Overview
  46. 8.8.3 MindMed Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 MindMed Psilocybin Assisted Therapy Product Portfolio
  48. 8.8.5 MindMed Recent Developments
  49. 8.9 Verrian
  50. 8.9.1 Verrian Company Information
  51. 8.9.2 Verrian Business Overview
  52. 8.9.3 Verrian Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Verrian Psilocybin Assisted Therapy Product Portfolio
  54. 8.9.5 Verrian Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Psilocybin Assisted Therapy Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Psilocybin Assisted Therapy Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Psilocybin Assisted Therapy Value Chain Analysis
  2. 9.1.1 Psilocybin Assisted Therapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Psilocybin Assisted Therapy Sales Mode & Process
  6. 9.2 Psilocybin Assisted Therapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Psilocybin Assisted Therapy Distributors
  9. 9.2.3 Psilocybin Assisted Therapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst